Qiagen (QGEN) investor relations material

Financial performance and outlook

• Q1 2026 net sales reached $492 million, up 2% reported but down 1% at constant exchange rates, with adjusted diluted EPS of $0.54, meeting outlook despite mixed sales trends and a challenging macro environment.

• Adjusted operating income margin for Q1 was about 27.4%, reflecting efficiency gains and absorbing headwinds from tariffs, currency, and acquisitions.

• Four out of five growth pillars met or exceeded expectations, with strong contributions from Sample Technologies and QIAcuity.

• QuantiFERON sales declined 5% CER due to lower immigration testing demand, while other patient testing groups remained solid.

• 2026 outlook updated: net sales expected to grow 1%-2% CER (down from at least 5%), and adjusted diluted EPS to be at least $2.43 CER (down from $2.50).

Segment and product performance

• Sample Technologies sales grew 9% CER, driven by automation, instrument placements, and Parse integration, which is on track to exceed $40 million in 2026 sales.

• QIAcuity achieved double-digit CER growth, driven by instrument placements and consumables expansion.

• QIAGEN Digital Insights saw solid single-digit CER growth, especially in clinical bioinformatics.

• QIAstat diagnostics sales declined 1% CER, but consumables for GI and meningitis panels grew double digits.

• PCR nucleic acid sales fell 13% CER, with softness in PCR consumables and OEM business due to life science funding constraints.

QuantiFERON and market dynamics

• QuantiFERON immigration testing represents about 10% of total QuantiFERON sales; the decline is isolated to this segment.

• Underlying latent TB testing market continues to grow at 4%-5% globally, with U.S. growth now about 1 percentage point lower.

• New automation and workflow enhancements for QuantiFERON are being rolled out, with further details to be shared in a May 7th spotlight session.

• No significant competitive pressure identified; new entrants are seen as technologically behind current offerings.

• QuantiFERON full-year 2026 sales now expected to be flat at CER versus 2025, reflecting rebased immigration testing demand.